Evidence map›Paper›PMID 40904819›Full record

ArticleFrontiers in artificial intelligence2025

From data silos to insights: the PRINCE multi-agent knowledge engine for preclinical drug development.

Carlos Henrique Vieira-Vieira, Sarang Sanjay Kulkarni, Adam Zalewski, Jobst Löffler, Jonas Münch, Annika Kreuchwig

Abstract read
In one paragraph

Article in Frontiers in artificial intelligence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Carlos Henrique Vieira-Vieira *Bayer Research and Development, Pharmaceuticals, Preclinical Development, Berlin, Germany.
Sarang Sanjay Kulkarni *Thoughtworks Technologies (India) Private Ltd., Pune, India.
Adam ZalewskiBayer Research and Development, Pharmaceuticals, Preclinical Development, Berlin, Germany.
Jobst LöfflerBayer Pharma Drug Innovation, Technology and Engineering, Leverkusen, Germany.
Jonas MünchBayer Digital Transformation and IT Pharma, Berlin, Germany.
Annika KreuchwigBayer Research and Development, Pharmaceuticals, Preclinical Development, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The pharmaceutical industry faces pressure to improve the drug development process while reducing costs in an evolving regulatory landscape. This paper presents the Preclinical Information Center (PRINCE), a cloud-hosted data integration platform developed by Bayer AG in collaboration with Thoughtworks. PRINCE integrates decades of structured and unstructured safety study reports, leveraging a multi-agent architecture based on Large Language Models (LLMs) and advanced data retrieval methodologies, such as Retrieval-Augmented Generation and Text-to-SQL. In this paper, we describe the three-step evolution of PRINCE from a data search tool based on keyword matching to a resourceful research assistant capable of answering complex questions and drafting regulatory-critical documents. We highlight the iterative development process, guided by user feedback, that ensures alignment with evolving research needs and maximizes utility. Finally, we discuss the importance of building trust-based solutions and how transparency and explainability have been integrated into PRINCE. In particular, the integration of a human-in-the-loop approach enhances the accuracy and retains human accountability. We believe that the development and deployment of the PRINCE chatbot demonstrate the transformative potential of AI in the pharmaceutical industry, significantly improving data accessibility and research efficiency, while prioritizing data governance and compliance.

Indexed as

agentic artificial intelligencechatbotgenerative artificial intelligencelarge-language modelpharmaceutical industrypreclinicalregulatory document generationretrieval-augmented generation

Identifiers

PMID40904819
PMCPMC12401995

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.